The LSIS points to the success and continuing growth of the NE cluster and highlights the region as an exemplar of successful Government policy and investment from the late 1960s and early 1970s.
The conclusion is based on an interim report to Government published by First for Pharma, CPI, and the North East LEP.
Sir John Bell, Regius Professor of Medicine at Oxford University, has worked with the Office for Life Sciences and the Life Sciences Industrial Strategy Board to make recommendations to Government.
A set of recommendations key to pharma manufacturers in the North East is to support the growth of existing life science clusters and to attract substantial investment to manufacture and export high value life science products. A target of £2-3bn of investment is set in the report.
First for Pharma’s interim report indicates that three quarters of pharma product manufactured in the region is exported to the USA.
The LSIS also recommends additional investment in basic and translational life sciences and in the NHS; it sees the NHS as a key element in improving health and wealth through close collaboration with industry and the widespread adoption of digital technologies.
Most striking is the call to create a Health Advanced Research Programme (HARP) that will create two to three entirely new industries in the UK over the next 10 years.